Breaking Ground in T Cell Therapy: Pan Cancer T Secures $4.25 Million in Seed Funding

Pan Cancer T, a biotechnology spin-out from Erasmus MC in Rotterdam, has successfully raised $4.25 million in funding.

Specializing in the discovery and development of T cell receptor (TCR) T cell therapies, the company leverages two decades of expertise in adoptive T cell therapy to revolutionize the treatment of solid tumors.

This recent funding injection will enable Pan Cancer T to further advance their natural affinity TCR T cell therapies targeting exclusive intracellular markers found across various solid tumors.

By prioritizing accessibility to T cell therapy amidst the complexities of the tumor micro-environment, Pan Cancer T is paving the way for groundbreaking solutions in cancer treatment.

This financial support will propel the company's research and development efforts as they continue to push the boundaries of innovative cancer therapies.